Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B; Harrington, KJ; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Baste, N; Neupane, P; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Hong, RL; Mendoza, RG; Roy, A; Zhang, YY; Gumuscu, B; Cheng, JD; Jin, F; Rischin, D LANCET. 2019; 394(10212): 1915-1928.

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

Rucker, FG; Agrawal, M; Corbacioglu, A; Weber, D; Kapp-Schwoerer, S; Gaidzik, VI; Jahn, N; Schroeder, T; Wattad, M; Lubbert, M; Koller, E; Kindler, T; Gotze, K; Ringhoffer, M; Westermann, J; Fiedler, W; Horst, HA; Greil, R; Schroers, R; Mayer, K; Heinicke, T; Krauter, J; Schlenk, RF; Thol, F; Heuser, M; Ganser, A; Bullinger, L; Paschka, P; Dohner, H; Dohner, K BLOOD. 2019; 134(19): 1608-1618.

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Valent, P; Orazi, A; Savona, MR; Patnaik, MM; Onida, F; van de Loosdrecht, AA; Haase, D; Haferlach, T; Elena, C; Pleyer, L; Kern, W; Pemovska, T; Vladimer, GI; Schanz, J; Keller, A; Lubbert, M; Lion, T; Sotlar, K; Reiter, A; De Witte, T; Pfeilstocker, M; Geissler, K; Padron, E; Deininger, M; Orfao, A; Horny, HP; Greenberg, PL; Arber, DA; Malcovati, L; Bennett, JM HAEMATOLOGICA. 2019; 104(10): 1935-1949.

Epidemiology and Treatment of Patients with Haemophilia in Austria-Update from the Austrian Haemophilia Registry.

Rejto, J; Reitter-Pfoertner, S; Kepa, S; Feistritzer, C; Grundbichler, M; Horbst, A; Jones, N; Muntean, W; Neumeister, P; Oberbichler, S; Schuster, G; Schwarz, R; Thom, K; Zwiauer, K; Streif, W; Male, C; Pabinger, I HAMOSTASEOLOGIE. 2019; 39(3): 284-293.

Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).

Gampenrieder, SP; Peer, A; Weismann, C; Meissnitzer, M; Rinnerthaler, G; Webhofer, J; Westphal, T; Riedmann, M; Meissnitzer, T; Egger, H; Klaassen Federspiel, F; Reitsamer, R; Hauser-Kronberger, C; Stering, K; Hergan, K; Mlineritsch, B; Greil, R; Breast Cancer Res. 2019; 21(1):19

MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.

Schwarzenbacher, D; Klec, C; Pasculli, B; Cerk, S; Rinner, B; Karbiener, M; Ivan, C; Barbano, R; Ling, H; Wulf-Goldenberg, A; Stanzer, S; Rinnerthaler, G; Stoeger, H; Bauernhofer, T; Haybaeck, J; Hoefler, G; Jahn, SW; Parrella, P; Calin, GA; Pichler, M; Breast Cancer Res. 2019; 21(1): 20

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.

Rinnerthaler, G; Gampenrieder, SP; Greil, R; Int J Mol Sci. 2019; 20(5):

Carcinoid heart disease involving the left heart: a case report and biomarker analysis.

Lichtenauer, M; Pichler, T; Eder, S; Mirna, M; Magnes, T; Wernly, B; Paar, V; Jung, C; Prinz, E; Seitelberger, R; Hoppe, UC; ESC Heart Fail. 2019; 6(1): 222-227.

Mouse models to decipher anti-tumor immunity.

Parigger, T; Greil, R; Zaborsky, N; Oncotarget. 2019; 10(49):-5006.

Good Response of Lupus Hepatitis to Mycophenolate Mofetil and Belimumab as of Lupus Exanthema to Rituximab: A Case Report

Psenak, O; Studnicka-Benke, A; Haufe, H; Greil, R; Rheumatology: Current Research. 2019; 9(1): 247-251.